tradingkey.logo

Brainsway Ltd

BWAY
19.370USD
+0.080+0.41%
Close 12/26, 16:00ETQuotes delayed by 15 min
368.10MMarket Cap
58.76P/E TTM

Brainsway Ltd

19.370
+0.080+0.41%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Brainsway Ltd

Currency: USD Updated: 2025-12-26

Key Insights

Brainsway Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 63/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Brainsway Ltd's Score

Industry at a Glance

Industry Ranking
63 / 207
Overall Ranking
174 / 4563
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
23.500
Target Price
+32.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Brainsway Ltd Highlights

StrengthsRisks
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.92% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.02M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 58.76, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.12M shares, increasing 8.58% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 313.16K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-12-26

The current financial score of Brainsway Ltd is 8.81, ranking 28/207 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 13.51M, representing a year-over-year increase of 28.66%, while its net profit experienced a year-over-year increase of 136.56%.

Score

Industry at a Glance

Previous score
8.81
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.89

Operational Efficiency

8.97

Growth Potential

9.66

Shareholder Returns

7.55

Brainsway Ltd's Company Valuation

Currency: USD Updated: 2025-12-26

The current valuation score of Brainsway Ltd is 4.12, ranking 199/207 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 58.76, which is 702.02% below the recent high of 471.25 and 343.52% above the recent low of -143.09.

Score

Industry at a Glance

Previous score
4.12
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 63/207
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-26

The current earnings forecast score of Brainsway Ltd is 8.00, ranking 59/207 in the Healthcare Equipment & Supplies industry. The average price target for Brainsway Ltd is 23.50, with a high of 24.00 and a low of 23.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
23.500
Target Price
+32.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

90
Total
4
Median
7
Average
Company name
Ratings
Analysts
Brainsway Ltd
BWAY
2
Boston Scientific Corp
BSX
36
Intuitive Surgical Inc
ISRG
34
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
27
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-26

The current price momentum score of Brainsway Ltd is 9.72, ranking 2/207 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 20.87 and the support level at 16.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.73
Change
-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.460
Buy
RSI(14)
66.369
Neutral
STOCH(KDJ)(9,3,3)
86.321
Overbought
ATR(14)
0.854
High Vlolatility
CCI(14)
111.869
Buy
Williams %R
11.227
Overbought
TRIX(12,20)
0.509
Sell
StochRSI(14)
80.642
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
18.846
Buy
MA10
17.785
Buy
MA20
17.604
Buy
MA50
16.622
Buy
MA100
15.765
Buy
MA200
13.128
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-26

The current institutional shareholding score of Brainsway Ltd is 3.00, ranking 135/207 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 32.49%, representing a quarter-over-quarter decrease of 2.95%. The largest institutional shareholder is James Simons, holding a total of 313.16K shares, representing 1.60% of shares outstanding, with 1.27% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Valor Equity Partners
2.10M
--
Masters Capital Management, L.L.C.
1.00M
--
Phoenix Financial Ltd
697.26K
+190.09%
Acadian Asset Management LLC
334.27K
-0.69%
Renaissance Technologies LLC
Star Investors
283.86K
-4.83%
Essex Investment Management Company, LLC
300.94K
-0.73%
Shulkin (Jonathan K.)
268.25K
--
Gracias (Antonio J)
243.50K
--
Two Sigma Investments, LP
172.60K
+1.07%
Cresset Asset Management, LLC
157.46K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-12-26

The current risk assessment score of Brainsway Ltd is 4.28, ranking 111/207 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.28
Change
0
Beta vs S&P 500 index
1.19
VaR
+5.29%
240-Day Maximum Drawdown
+32.24%
240-Day Volatility
+59.14%

Return

Best Daily Return
60 days
+10.49%
120 days
+14.41%
5 years
+19.27%
Worst Daily Return
60 days
-5.83%
120 days
-5.83%
5 years
-31.56%
Sharpe Ratio
60 days
+2.35
120 days
+1.79
5 years
+0.59

Risk Assessment

Maximum Drawdown
240 days
+32.24%
3 years
+36.33%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+3.27
3 years
+8.15
5 years
+0.25
Skewness
240 days
+0.96
3 years
+0.57
5 years
-0.13

Volatility

Realised Volatility
240 days
+59.14%
5 years
--
Standardised True Range
240 days
+3.25%
5 years
+2.09%
Downside Risk-Adjusted Return
120 days
+388.92%
240 days
+388.92%
Maximum Daily Upside Volatility
60 days
+43.49%
Maximum Daily Downside Volatility
60 days
+35.67%

Liquidity

Average Turnover Rate
60 days
+0.17%
120 days
+0.14%
5 years
--
Turnover Deviation
20 days
-9.76%
60 days
-33.96%
120 days
-46.97%

Peer Comparison

Healthcare Equipment & Supplies
Brainsway Ltd
Brainsway Ltd
BWAY
7.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
Tactile Systems Technology Inc
TCMD
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Brainsway Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Brainsway Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Brainsway Ltd’s performance and outlook.

How do we generate the financial health score of Brainsway Ltd?

To generate the financial health score of Brainsway Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Brainsway Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Brainsway Ltd.

How do we generate the company valuation score of Brainsway Ltd?

To generate the company valuation score of Brainsway Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Brainsway Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Brainsway Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Brainsway Ltd.

How do we generate the earnings forecast score of Brainsway Ltd?

To calculate the earnings forecast score of Brainsway Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Brainsway Ltd’s future.

How do we generate the price momentum score of Brainsway Ltd?

When generating the price momentum score for Brainsway Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Brainsway Ltd’s prices. A higher score indicates a more stable short-term price trend for Brainsway Ltd.

How do we generate the institutional confidence score of Brainsway Ltd?

To generate the institutional confidence score of Brainsway Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Brainsway Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Brainsway Ltd.

How do we generate the risk management score of Brainsway Ltd?

To assess the risk management score of Brainsway Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Brainsway Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Brainsway Ltd.
KeyAI